0.40Open0.45Pre Close79 Volume963 Open Interest12.50Strike Price3.90KTurnover60.18%IV4.93%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type-0.4520Delta0.2651Gamma22.85Leverage Ratio-0.0204Theta-0.0022Rho-10.33Eff Leverage0.0099Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet